ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Digoxin

Also written as “digoxin”, “ZT002 injection, rosuvastatin, digoxin” and “Digoxin (0.25mg)”.

Its studies are mostly in Obesity · Neoplasms · Thalassemia · Carcinoma, Non-Small-Cell Lung · Liver Cirrhosis, led by 25 companies.

Drug pageDigoxin: every studyMany companies study it; this page follows only the 43 they lead. All 87 studies, academic ones too, with its approvals and label.
Furthest: phase 2, since Jun 1, 201043 company-led studies, 1 open or runningNext primary completion: Dec 5, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only90 open or runningphase 1since Jun 1, 2010Jun 1, 2010none ahead
AstraZenecaits history only30 open or runningphase 1since Jul 8, 2008Jul 8, 2008none ahead
Bristol-Myers Squibbits history only30 open or runningphase 1since Oct 9, 2014Oct 9, 2014none ahead
Astellas Pharmaits history only20 open or runningphase 1since Apr 29, 2014Apr 29, 2014none ahead
GlaxoSmithKlineits history only20 open or runningphase 1since Mar 28, 2008Mar 28, 2008none ahead
Hoffmann-La Roche20 open or runningphase 1since Jan 9, 2013Jan 9, 2013none ahead
Johnson & Johnsonits history only20 open or runningphase 1since Jan 20, 2011Jan 20, 2011none ahead
Merckits history only20 open or runningphase 1since Aug 26, 2024Aug 26, 2024none ahead
Sanofiits history only20 open or runningphase 1since May 19, 2011May 19, 2011none ahead
AbbVieits history only10 open or runningphase 1since Feb 3, 2016Feb 3, 2016none ahead

Also a collaborator on its studies: Parexel, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2013First study: phase 1 study in MelanomaFirst studyNCT01765569 · 29 enrolled · Belarus, Israel, Korea, Republic of and more
  2. Nov 5, 2024Phase 1 study in Healthy ParticipantsNCT06677957 · 19 enrolled · United States

TargetBeta

“Sodium/potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same 8 targets

ProgramCompanyFurthest phaseStudies
Istaroximerulewindtree-therapeuticsphase 38

Studies

All 2 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06677957Healthy Participants · United States1CompletedDec 30, 202419
NCT01765569Melanoma · Belarus, Israel, Korea, Republic of and more1CompletedJun 201429

How it is read

Names in the registry

  • “Digoxin”, 33 entries
  • “digoxin”, 6 entries
  • “ZT002 injection, rosuvastatin, digoxin”, 1 entry
  • “Digoxin (0.25mg)”, 1 entry
  • “Lenoxin®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.